Trial intelligence / Profile preview

GRADE

NCT01794143Phase 3Completed

Sponsor: GRADE Study Group
Start: May 2013
Primary completion: Apr 2021
Modality: Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
Countries: 1

Overview

Phase 3, randomised, open-label trial of glimepiride, sitagliptin, liraglutide and insulin glargine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by GRADE Study Group. Primary endpoints: Time to HbA1c >= 7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication and HbA1c >= 7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. Started May 2013; status: completed.

Drugs

glimepiridesitagliptinliraglutideinsulin glargine

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01794143.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01794143.